Cytotoxicity of Three Novel Fluoropyrimidines in Cultured L1210 Murine Lymphocytic Leukemia Cells

Abstract

Cultured L1210 murine lymphocytic leukemia cells were used to compare metabolic activation and cytotoxicity of 5-fluorouracil (FU), Ftorafur (FT), and three novel FU-sulfur analogues. These analogues, l-(2′-tetrahydrothienyl)-5-fluorouracil (FUS), l-(2′-tetrahydrothienyl)-5-fluorouracil-l′-oxide (FUSO), and 1-(2′-tetrahydrothienyl)-5-fluorouracil-l′-l′-dioxide (FUSO2), have yet to be fully evaluated for potential therapeutic value based on in vitro cytotoxicity. The role of these FU analogues as prodrugs was evaluated by comparing metabolism of normal pyrimidine pathways and activation by hepatic mixed function oxidases (MFO). Significant differences in biochemical activity and cytotoxicity were measured between FU and FU analogues. FU and FU analogues were cytotoxic to L1210 cells (63–92% growth inhibition of 100 µM concentrations after 72 hr of incubation). However, at equimolar concentrations cytotoxicity of the FU analogues after MFO activation (56–66% growth inhibition) was greater than FU (47% growth inhibition). Hypoxanthine, a purine precursor, did not significantly alter fluoropyrimidine cytotoxicity with or without MFO. Thymidine and uridine, pyrimidine precursors, reduced FT and FUS cytotoxicities in the presence (27, 40%) and absence (25, 15%) of MFO but did not modify FU, FUSO, or FUSO2 cytotoxicities.